HIBA PHARMA

000

KEZAD, Abu Dhabi

Est. 2021

Pharmaceutical Manufacturing Equipment

Manufacturing Capabilities

Built for the Most Complex Pharmaceutical Challenges

From sterile injectable oncology to solid oral dosage forms — HIBA Pharma delivers end-to-end manufacturing with full regulatory compliance at every stage.

Manufacturing Capabilities

End-to-End
Pharmaceutical Manufacturing

From formulation development through sterile fill-finish to final packaging — a vertically integrated manufacturing ecosystem built for the world's most demanding pharmaceutical requirements.

01

Sterile Injectable Manufacturing

Class A/B ISO 5/7 cleanroom environment for oncology injectables. Lyophilization, aseptic fill-finish, and automated visual inspection.

Sterile Injectable Manufacturing
LyophilizationAseptic Fill-FinishISO 5/7
02

Solid Oral Dosage Forms

High-throughput tablet and capsule manufacturing with containment systems for cytotoxic API handling. Capacity exceeding 0.5B units per annum.

Solid Oral Dosage Forms
TabletsCapsulesCytotoxic Containment
03

Analytical QC Laboratory

Full-service analytical laboratory with HPLC, GC-MS, ICP-MS, and microbiology suite supporting all ICH stability guidelines.

Analytical QC Laboratory
HPLCGC-MSICH Stability
04

Technology Transfer

Regulatory-compliant technology transfer with established partnerships across three continents. Proven from development through commercial scale.

Technology Transfer
Process ValidationRegulatory FilingsCMC Support
05

Contract Manufacturing

Flexible CMO services — from clinical batches to commercial-scale production for regional and international pharmaceutical companies.

Contract Manufacturing
CMOClinical ScaleCommercial Scale
06

Secondary Packaging

Automated serialization, track-and-trace, multi-language labelling, and cold-chain logistics integration at full GMP compliance.

Secondary Packaging
SerializationTrack & TraceCold Chain

Manufacturing Excellence

World-Class Facility.
Built for Scale.

16,000

Current Facility

Total operational footprint

14,000

Expansion Phase

Additional capacity planned

6,150

Production Area

cGMP clean-room manufacturing

2,600

Warehousing

Temperature-controlled storage

>0.5B

Tablets / Year

Solid oral dosage capacity

>0.25B

Capsules / Year

Hard gelatin capsule output

>40M

Vials / Year

Sterile injectable oncology

>100M

Packs / Year

Final packaged product

Facility Architecture

Six Integrated Operational Zones

Each zone is independently validated, temperature-controlled, and connected via GMP-compliant material flow paths.

01

cGMP Production

6,150
02

Sterile Injectable

Class A/BISO 5/7
03

Solid Oral Dosage

Class DISO 8
04

Controlled Warehousing

2,600
05

QC Laboratories

Full AnalyticalSuite
06

Critical Utilities

WFI / PurifiedWater Systems

UAE's only sterile injectable oncology manufacturing facility

HIBA Pharma manufacturing facility — KEZAD, Abu Dhabi

Location

KEZAD, Abu Dhabi, UAE

Khalifa Economic Zones Abu Dhabi